{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:35:54Z","timestamp":1787243754753,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1177\/2168479016671559","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T21:10:17Z","timestamp":1478293817000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patient Voice in Rare Disease Drug Development and Endpoints"],"prefix":"10.1007","volume":"51","author":[{"given":"Linda S.","family":"Deal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann J.","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Roberds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"key":"5102257_CR1","unstructured":"European Commission Report. Useful information on rare diseases from an EU perspective. Accessed May 2016."},{"key":"5102257_CR2","first-page":"e24","volume":"6","author":"S Gupta","year":"2012","unstructured":"Gupta S. Rare diseases: Canada\u2019s \u201cresearch orphans.\u201d Open Med. 2012;6:e24\u2013e27.","journal-title":"Open Med"},{"key":"5102257_CR3","unstructured":"Food and Drug Administration (FDA). Federal Food Drug and Cosmetic Act section 526(a)(2)(A) [21USC360bb]."},{"key":"5102257_CR4","unstructured":"World Health Organization. Background paper on orphan diseases for the WHO report on priority medicines for Europe and the world. Published Oct 7, 2004."},{"key":"5102257_CR5","volume-title":"Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development","author":"Rare diseases and orphan products: accelerating research and development","year":"2010","unstructured":"Rare diseases and orphan products: accelerating research and development. Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. In: Field MJ, Boat TF, eds. Washington, DC: National Academies Press; 2010."},{"key":"5102257_CR6","unstructured":"Global Genes: Allies in Rare Disease. Rare diseases: facts and statistics. https:\/\/globalgenes.org\/rare-diseases-facts-statistics\/. Accessed May 2016."},{"key":"5102257_CR7","volume-title":"Guidance for Industry \u2014 Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"FoodDrug Administration FDA","year":"2009","unstructured":"Food and Drug Administration (FDA). Guidance for Industry \u2014 Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: Food & Drug Administration; 2009."},{"key":"5102257_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","volume":"16","author":"LS Matza","year":"2013","unstructured":"Matza LS, Patrick DL, Riley AW, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16:461\u2013479.","journal-title":"Value Health"},{"key":"5102257_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1\u2014Eliciting concepts for a new PRO instrument. Value Health. 2011;14:967\u2013977.","journal-title":"Value Health"},{"key":"5102257_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014Assessing respondent understanding. Value Health. 2011;14:978\u2013988.","journal-title":"Value Health"},{"key":"5102257_CR11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/bmj.324.7347.1193","volume":"324","author":"AA Stone","year":"2002","unstructured":"Stone AA, Shiffman S, Schwartz JE, et al. Subject non-compliance with paper diaries. Br Med J. 2002;324:1193\u20131194.","journal-title":"Br Med J"},{"key":"5102257_CR12","unstructured":"Hufford MR, Stone AA, Shiffman S, et al. Paper vs. electronic diaries: compliance and subject evaluations. Appl Clin Trials. 2002:38\u201343."},{"key":"5102257_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091415","volume":"4","author":"S Shiffman","year":"2008","unstructured":"Shiffman S, Stone AA, Hufford M. Ecological momentary assessment. Ann Rev Clin Psychol. 2008;4:1\u201332.","journal-title":"Ann Rev Clin Psychol"},{"key":"5102257_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1037\/a0015197","volume":"28","author":"S Shiffman","year":"2009","unstructured":"Shiffman S. How many cigarettes did you smoke? assessing cigarette consumption by global report, time-line follow-back, and ecological momentary assessment. Health Psychol. 2009;28:519\u2013526.","journal-title":"Health Psychol"},{"key":"5102257_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"L McLeod","year":"2011","unstructured":"McLeod L, Coon C, Martin S, Fehnel S, Hays R. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163\u2013169.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5102257_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","volume":"53","author":"EM Perfetto","year":"2015","unstructured":"Perfetto EM, Burke L, Oehrlein EM, Epstein RS. Patient-focused drug development: a new direction for collaboration. Med Care 2015;53:9\u201317.","journal-title":"Med Care"},{"key":"5102257_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","volume":"36","author":"HL Peay","year":"2014","unstructured":"Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36:624\u2013637.","journal-title":"Clin Ther"},{"key":"5102257_CR18","unstructured":"The Prescription Drug User Fee Act V (PDUFA-V) reauthorized in July, 2012 by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012. http:\/\/www.fda.gov\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/ucm272170.htm. Accessed June 2016."},{"key":"5102257_CR19","unstructured":"Food and Drug Administration Safety and Innovation Act (FDASIA) (2012). [PL 112-144]. https:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-112publ144\/pdf\/PLAW-112publ144.pdf. Accessed June 2016."},{"key":"5102257_CR20","unstructured":"Rare diseases: common issues in drug development draft guidance, August 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM458485.pdf. Accessed June 2016."},{"key":"5102257_CR21","unstructured":"Described at 21CFR314.126 \u2014 Code of Federal Regulations. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.126. Accessed June 2016."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479016671559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2168479016671559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1177\/2168479016671559\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2168479016671559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479016671559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T09:02:18Z","timestamp":1598000538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1177\/2168479016671559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["5102257"],"URL":"https:\/\/doi.org\/10.1177\/2168479016671559","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"16 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}